Previous 10 | Next 10 |
2024-03-15 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-10 08:39:57 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
2024-03-08 10:21:57 ET More on Teva Pharmaceutical Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Position A Review Of Teva's Prospects UroGen falls as Te...
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 44 th Annual Health Care Conference on March 5, 2024 at 10:30 a.m. ET. The webcast will be accessible from Royalty Pharma’...
2024-02-18 23:32:12 ET Summary Royalty Pharma delivered outstanding results in 2023 and deployed capital in key value-enhancing transactions. The company increased its dividend per share by 5% and reported adjusted cash receipts that exceeded internal expectations. Royalty Pha...
2024-02-15 13:39:09 ET Royalty Pharma PLC (RPRX) Q4 2023 Earnings Conference Call February 15, 2024, 8:00 a.m. ET Company Participants Pablo Legorreta - Founder, Chairman & CEO Chris Hite - Vice Chairman & EVP Terrance Coyne - EVP & CFO Marshall U...
Portfolio Receipts of $736 million in Q4 2023 and $3,049 million for FY 2023 Net cash provided by operating activities of $773 million in Q4 2023 and $2,988 million for FY 2023 Announced transactions of up to $4.0 billion in 2023 Full year 2024 guidance: Portfolio Rece...
2024-02-11 08:19:38 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
2024-02-08 09:10:29 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to i...
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous...
News, Short Squeeze, Breakout and More Instantly...
Tuesday, Agios Pharmaceuticals Inc (NASDAQ:AGIO) agreed to sell its rights to its 15% royalty on potential U.S. net sales ...
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clini...
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20,...